Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Coya Therapeutics Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Gain Therapeutics Inc. June 24, 202694.6%
-
Gain Therapeutics Inc. June 24, 202599.5%
-
Gain Therapeutics Inc. June 24, 202495.8%
-
Coya Therapeutics Inc. May 8, 202477.1%
-
Gain Therapeutics Inc. June 23, 202397.9%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 23, 2026 | BioAge Labs Inc. | Option exercise | +3,542 | $4.38 | $15,514 |
| Mar 1, 2026 | BioAge Labs Inc. | Option exercise | +3,542 | $4.38 | $15,514 |
| Feb 1, 2026 | BioAge Labs Inc. | Option exercise | +3,541 | $4.38 | $15,510 |
| Jan 16, 2026 | BioAge Labs Inc. | Option exercise | +3,542 | $4.38 | $15,514 |
| Jan 13, 2026 | BioAge Labs Inc. | Option exercise | +27,000 | $8.39 | $226,530 |
| Jan 13, 2026 | BioAge Labs Inc. | Open-market sale | −8,974 | $18.43 | $165,391 |
| Jan 13, 2026 | BioAge Labs Inc. | Open-market sale | −4,440 | $19.45 | $86,358 |
| Jan 13, 2026 | BioAge Labs Inc. | Open-market sale | −11,663 | $20.54 | $239,558 |
| Jan 13, 2026 | BioAge Labs Inc. | Open-market sale | −1,923 | $21.08 | $40,537 |
| Aug 18, 2025 | Coya Therapeutics Inc. | Option exercise | +17,557 | $1.09 | $19,137 |
| Jan 3, 2023 | Coya Therapeutics Inc. | Open-market purchase | +10,000 | — | — |
Questions about Dov A. Goldstein M.D.
What boards is Dov A. Goldstein M.D. on?
Dov A. Goldstein M.D. sits on the boards of Coya Therapeutics Inc. and Gain Therapeutics Inc.
How long has Dov A. Goldstein M.D. served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.